HUMAN IMMUNODEFICIENCY VIRUS: ELUSIVE PERSPECTIVES AND NOVEL VACCINATION APPROACHES
DOI:
https://doi.org/10.22159/ijpps.2025v17i5.53841Keywords:
HIV, Vaccine, T-cells, B-cells, RV144, HVTN 505Abstract
A Human Immunodeficiency Virus (HIV) vaccine is a critical component in the effort to manage the global epidemic. To assess the current state of HIV vaccine development, we analyze the findings of effectiveness trials conducted to date, as well as the immunological principles that drove them. Four vaccine approaches have been evaluated in HIV-1 vaccine effectiveness trials. The results have offered valuable information for future vaccine development. While one of these trials demonstrated that a safe and effective HIV vaccine is feasible, numerous issues remain about the basis for the observed protection and the most effective strategy to stimulate it. Novel HIV vaccination techniques, such as inducing highly potent broadly neutralizing antibodies, novel homologous and heterologous vector systems, and vectored immunoprophylaxis, aim to expand and build on the knowledge obtained from previous trials.
Downloads
References
Alt FW, Zhang Y, Meng FL, Guo C, Schwer B. Mechanisms of programmed DNA lesions and genomic instability in the immune system. Cell. 2013;152(3):417-29. doi: 10.1016/j.cell.2013.01.007, PMID 23374339.
Baden LR, Blattner WA, Morgan C, Huang Y, Defawe OD, Sobieszczyk ME. Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. J Infect Dis. 2011;204(10):1541-9. doi: 10.1093/infdis/jir615, PMID 21940420.
Baden LR, Walsh SR, Seaman MS, Tucker RP, Krause KH, Patel A. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis. 2013;207(2):240-7. doi: 10.1093/infdis/jis670, PMID 23125444.
Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2011;481(7379):81-4. doi: 10.1038/nature10660, PMID 22139420.
Ramteke AS. Pathogenesis of human immunodeficiency virus, effective treatment and prevention strategy. Int J Pharm Sci. 2024;2:703-17.
Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012;482(7383):89-93. doi: 10.1038/nature10766, PMID 22217938.
Barouch DH, O’Brien KL, Simmons NL, King SL, Abbink P, Maxfield LF. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med. 2010;16(3):319-23. doi: 10.1038/nm.2089, PMID 20173752.
Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology. 2007;360(2):329-40. doi: 10.1016/j.virol.2006.10.032, PMID 17126869.
Berman PW, Murthy KK, Wrin T, Vennari JC, Cobb EK, Eastman DJ. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J Infect Dis. 1996;173(1):52-9. doi: 10.1093/infdis/173.1.52, PMID 8537682.
Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881-93. doi: 10.1016/S0140-6736(08)61591-3, PMID 19012954.
Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science. 2012;337(6091):183-6. doi: 10.1126/science.1225416, PMID 22798606.
Carrington M, O’Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med. 2003;54:535-51. doi: 10.1146/annurev.med.54.101601.152346, PMID 12525683.
Chen H, Ndhlovu ZM, Liu D, Porter LC, Fang JW, Darko S. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat Immunol. 2012;13(7):691-700. doi: 10.1038/ni.2342, PMID 22683743.
Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1–V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol. 2005;79(10):6528-31. doi: 10.1128/JVI.79.10.6528-6531.2005, PMID 15858037.
Cox KS, Clair JH, Prokop MT, Sykes KJ, Dubey SA, Shiver JW. DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles. J Virol. 2008;82(16):8161-71. doi: 10.1128/JVI.00620-08, PMID 18524823.
Derdeyn CA, Decker JM, Bibollet Ruche F, Mokili JL, Muldoon M, Denham SA. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science. 2004;303(5666):2019-22. doi: 10.1126/science.1093137, PMID 15044802.
De Souza MS, Ratto Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B. The thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol. 2012;188(10):5166-76. doi: 10.4049/jimmunol.1102756, PMID 22529301.
Dolin R, Graham BS, Greenberg SB, Tacket CO, Belshe RB, Midthun K. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network Ann Intern Med. 1991;114(2):119-27. doi: 10.7326/0003-4819-114-2-119, PMID 1984386.
Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol. 1997;15:617-48. doi: 10.1146/annurev.immunol.15.1.617, PMID 9143702.
Excler JL, Parks CL, Ackland J, Rees H, Gust ID, Koff WC. Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference. Biologicals. 2010;38(4):511-21. doi: 10.1016/j.biologicals.2010.03.005, PMID 20537552.
Fadda L, O’Connor GM, Kumar S, Piechocka Trocha A, Gardiner CM, Carrington M. Common HIV-1 peptide variants mediate differential binding of KIR3DL1 to HLA-Bw4 molecules. J Virol. 2011;85(12):5970-4. doi: 10.1128/JVI.00412-11, PMID 21471246.
Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: current progress. Clin Infect Dis. 2011;53(3):296-302. doi: 10.1093/cid/cir334, PMID 21765081.
Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med. 2007;13(1):100-6. doi: 10.1038/nm1461, PMID 17187074.
Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191(5):654-65. doi: 10.1086/428404, PMID 15688278.
Frost SD, Liu Y, Pond SL, Chappey C, Wrin T, Petropoulos CJ. Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol. 2005;79(10):6523-7. doi: 10.1128/JVI.79.10.6523-6527.2005, PMID 15858036.
Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis. 2010;202(4):595-605. doi: 10.1086/654816, PMID 20608874.
Girard MP, Osmanov S, Assossou OM, Kieny MP. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine. 2011;29(37):6191-218. doi: 10.1016/j.vaccine.2011.06.085, PMID 21718747.
Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis. 2011;203(5):610-9. doi: 10.1093/infdis/jiq105, PMID 21282192.
Goepfert PA, Horton H, McElrath MJ, Gurunathan S, Ferrari G, Tomaras GD. High-dose recombinant canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis. 2005;192(7):1249-59. doi: 10.1086/432915, PMID 16136469.
Gomez CE, Perdiguero B, Garcia Arriaza J, Esteban M. Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother. 2012;8(9):1192-207. doi: 10.4161/hv.20778, PMID 22906946.
Gorny MK, Stamatatos L, Volsky B, Revesz K, Williams C, Wang XH. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol. 2005;79(8):5232-7. doi: 10.1128/JVI.79.8.5232-5237.2005, PMID 15795308.
Gottlieb GS, Heath L, Nickle DC, Wong KG, Leach SE, Jacobs B. HIV-1 variation before seroconversion in men who have sex with men: analysis of acute/early HIV infection in the multicenter AIDS cohort study. J Infect Dis. 2008;197(7):1011-5. doi: 10.1086/529206, PMID 18419538.
Greenier JL, Miller CJ, Lu D, Dailey PJ, Lu FX, Kunstman KJ. Route of simian immunodeficiency virus inoculation determines the complexity but not the identity of viral variant populations that infect rhesus macaques. J Virol. 2001;75(8):3753-65. doi: 10.1128/JVI.75.8.3753-3765.2001, PMID 11264364.
Griffiss JM, Goroff DK. IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms. J Immunol. 1983;130(6):2882-5. PMID 6854021.
Grundner C, Li Y, Louder M, Mascola J, Yang X, Sodroski J. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology. 2005;331(1):33-46. doi: 10.1016/j.virol.2004.09.022, PMID 15582651.
Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne Johnson L. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011;473(7348):523-7. doi: 10.1038/nature10003, PMID 21562493.
Hemelaar J. The origin and diversity of the HIV-1 pandemic. Trends Mol Med. 2012;18(3):182-92. doi: 10.1016/j.molmed.2011.12.001, PMID 22240486.
Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med. 2009;15(8):951-4. doi: 10.1038/nm.1974, PMID 19525965.
Huang J, Ofek G, Laub L, Louder MK, Doria Rose NA, Longo NS. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012;491(7424):406-12. doi: 10.1038/nature11544, PMID 23151583.
Jarvis GA, Griffiss JM. Human IgA1 blockade of IgG-initiated lysis of Neisseria meningitidis is a function of antigen-binding fragment binding to the polysaccharide capsule. J Immunol. 1991;147(6):1962-7. PMID 1909736.
Johnston MI, Fauci AS. HIV vaccine development-improving on natural immunity. N Engl J Med. 2011;365(10):873-5. doi: 10.1056/NEJMp1107621, PMID 21899447.
Keefer MC, Graham BS, Belshe RB, Schwartz D, Corey L, Bolognesi DP. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network AIDS Res Hum Retrovir. 1994;10(12):1713-23. doi: 10.1089/aid.1994.10.1713, PMID 7888231.
Keele BF, Giorgi EE, Salazar Gonzalez JF, Decker JM, Pham KT, Salazar MG. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA. 2008;105(21):7552-7. doi: 10.1073/pnas.0802203105, PMID 18490657.
Kim M, Qiao ZS, Montefiori DC, Haynes BF, Reinherz EL, Liao HX. Comparison of HIV type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. AIDS Res Hum Retrovir. 2005;21(1):58-67. doi: 10.1089/aid.2005.21.58, PMID 15665645.
Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull. 2001;58:19-42. doi: 10.1093/bmb/58.1.19, PMID 11714622.
Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013;496(7446):469-76. doi: 10.1038/nature12053, PMID 23552890.
MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis. 1998;178(1):92-100. doi: 10.1086/515613, PMID 9652427.
Mathew GD, Qualtiere LF, Neel HB, Pearson GR. IgA antibody, antibody-dependent cellular cytotoxicity and prognosis in patients with nasopharyngeal carcinoma. Int J Cancer. 1981;27(2):175-80. doi: 10.1002/ijc.2910270208, PMID 6169655.
McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity. 2010;33(4):542-54. doi: 10.1016/j.immuni.2010.09.011, PMID 21029964.
Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis. 2012;206(3):431-41. doi: 10.1093/infdis/jis367, PMID 22634875.
Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol. 2011;85(7):3128-41. doi: 10.1128/JVI.02658-10, PMID 21270156.
Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012;18(11):1688-92. doi: 10.1038/nm.2985, PMID 23086475.
Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol. 2006;24:739-69. doi: 10.1146/annurev.immunol.24.021605.090557, PMID 16551265.
Santra S, Liao HX, Zhang R, Muldoon M, Watson S, Fischer W. Mosaic vaccines elicit CD8+T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med. 2010;16(3):324-8. doi: 10.1038/nm.2108, PMID 20173754.
Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA. Control of viremia in simian immunodeficiency virus infection by CD8+lymphocytes. Science. 1999;283(5403):857-60. doi: 10.1126/science.283.5403.857, PMID 9933172.
Schwartz DH, Gorse G, Clements ML, Belshe R, Izu A, Duliege AM. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine. Lancet. 1993;342(8863):69-73. doi: 10.1016/0140-6736(93)91283-r, PMID 8100910.
Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477(7365):466-70. doi: 10.1038/nature10373, PMID 21849977.
Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326(5950):285-9. doi: 10.1126/science.1178746, PMID 19729618.
Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science. 1992;255(5048):1134-7. doi: 10.1126/science.1546316, PMID 1546316.
Published
How to Cite
Issue
Section
Copyright (c) 2025 ASHISH S. RAMTEKE
This work is licensed under a Creative Commons Attribution 4.0 International License.
